Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms

Pharmiweb.com RSS Feed Pharmiweb.com RSS Feeds

Advertising

Press Release

Marrone Bio Innovations Announces the Availability of Amplitude™ Biofungicide for White Mold Control in the 2018 Growing Season


Posted on: 08 Dec 17

DAVIS, Calif., Dec. 08, 2017 (GLOBE NEWSWIRE) -- Marrone Bio Innovations, Inc. (NASDAQ:MBII) (MBI), a leading provider of bio-based pest management and plant health products for agriculture, turf and ornamental and water treatment markets, today announced the launch and availability of a high-performance and cost-effective biological fungicide, Amplitude™, in the 2018 growing season. Using the same active ingredient in the recently EPA approved Stargus™, Amplitude expands the use of this exciting new product to large acre crops.

Amplitude is based on a new strain of Bacillus amyloliquefaciens, discovered by MBI, that has shown strong performance against white molds and soil diseases such as Phytophthora, Rhizoctonia (pink rot and black scurf of potatoes), and Fusarium, as shown in field trials in the U.S., Canada and Europe.

When assessing the market place, MBI has identified that growers have often struggled to find great performing products for white mold in those important crops.   They have few choices of products that perform well on the group of fungi that causes white molds on pulses, dry beans, bulb vegetables, soybeans, canola and sunflower. Amplitude™, which addresses this specific market need, is the direct result of MBI’s directed screening discovery program. This product is also complementary and additive to the broad spectrum of diseases covered by MBI’s first biofungicide, Regalia®, providing a solid one-two punch in controlling white molds and soil diseases. MBI and partners also are testing this Bacillus-based product for seed treatment applications.

“We are pleased to provide growers with this unique tool to control white molds and soil diseases on a broad range of large acre crops, as well as on pulse, tuber and root crops. The development of this product is particularly timely in light of the development of resistance to conventional fungicide products. Amplitude can be used alone, but can also be combined with a conventional fungicide for a great ROI,” said André Trépanier, MBI’s Director of Marketing. “White mold tends to be a devastating disease in these crops, often causing significant economic damage if left unchecked.”

Tests conducted at MBI’s research and development lab show that AmplitudeTM works by colonizing a plant’s root hairs, stems and other surfaces to prevent establishment of fungal and bacterial pathogens, including Fusarium, Sclerotinia, Rhizoctonia, Verticillium, Phytophthora and Sclerotium. Test results also indicated that the bacterium produces natural compounds, some of which inhibit bacterial and fungal mycelial growth, as well as spore germination. In addition, the bacteria trigger systemic acquired resistance and induced systemic responses in the plant, creating a healthier and stronger plant to ward off diseases and promote plant health, growth and increased yield.  MBI has been issued a patent on the novel strain used in AmplitudeTM.

Extensive field studies with growers have confirmed and demonstrated excellent efficacy against white mold on various pulse crops, soybean, sunflower and canola, as well as Cercospora leaf spot on sugar beets. Testing for soil applications on potatoes for control of Rhizoctonia (Black scurf) and Phytophthora eurythroseptica (pink rot) have also delivered excellent results. Successful field trials have been conducted in the United States, Mexico, Canada and Europe.
                                                     
The biofungicide product has also been submitted to Canada and Mexico for approval and the dossier is being prepared for the European Union. In the United States, pulse crop and potato acres affected by white mold increase yearly. In pulse crops like lentils, the yield loss to white mold can easily reach 50%. Canada and Europe are expected to grow 9.3 million and 6.7 million hectares of Canola (oilseed rape) in 2017 respectively1; white mold is the most serious disease facing these crops.

1 Canola Council of Canada, European Commission on Agriculture and Rural Development

About Marrone Bio Innovations

Smart. Natural. Solutions.
Marrone Bio Innovations, Inc. (NASDAQ: MBII) strives to lead the movement to a more sustainable world through the discovery, development and promotion of biological products for pest management and plant health. MBI’s effective and environmentally responsible pest management solutions help customers operate more sustainably while uniquely improving plant health and increasing crop yields. MBI currently has seven commercially available products (Regalia®, Grandevo®, Venerate®, Majestene®, Haven® Stargus™ and Zequanox®) as well as seven product candidates in various stages of the company’s rapid development pipeline. MBI also distributes Bio-tam 2.0® for Isagro USA and Jet-Ag® for Jet Harvest in most regions of the U.S.

Marrone Bio Innovations is dedicated to pioneering smart biopesticide solutions that support a better tomorrow for both farmers and consumers around the globe.  For more information, please visit www.marronebio.com.

Marrone Bio Innovations Forward Looking Statements
This press release contains forward-looking statements that involve substantial risks and uncertainties.  All statements, other than statements of historical facts, included in this press release regarding strategy, future operations and plans, including assumptions underlying such statements, are forward-looking statements, and should not be relied upon as representing MBI’s views as of any subsequent date.  Examples of such statements include statements regarding the potential of Amplitude in the market, market projections, including the potential benefits of Amplitude, and MBI’s plans for expanding additional label uses and international expansion. Such forward-looking statements are based on information available to the Company as of the date of this release and involve a number of risks and uncertainties, some beyond the Company's control, that could cause actual results to differ materially from those anticipated by these forward-looking statements, including consumer, regulatory and other factors affecting demand for the MBI’s products, any difficulty in marketing MBI’s products in its target markets inside and outside the United States, competition in the market for pest management products, lack of understanding of bio-based pest management products by customers and growers.  Additional information that could lead to material changes in MBI’s performance is contained in its filings with the SEC.  MBI is under no obligation to, and expressly disclaims any responsibility to, update or alter forward-looking statements contained in this release, whether as a result of current information, future events or otherwise.

Marrone Bio Innovations Contacts:
Pam Marrone, CEO and Founder
Andre Trepanier, Director of Marketing
Telephone: +1 (530) 750-2800
Email: Info@marronebio.com

MBI Investor Relations:
Greg Falesnik
Managing Director
MZ Group – MZ North America
Main: 949-385-6449
MBII@mzgroup.us         
www.mzgroup.us

GlobeNewswire
globenewswire.com

Last updated on: 11/12/2017

Advertising
Site Map | Privacy & Security | Cookies | Terms and Conditions

PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.